Javier Pinilla-Ibarz, MD, PhD

Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the current treatment landscape of chronic lymphocytic leukemia (CLL).

Over the last 5 to 10 years, Pinilla-Ibarz says the landscape has changed dramatically. In the past, there were only monoclonal antibodies and chemotherapy, but now a number of new treatments have been introduced to this patient population, including B-cell receptor inhibitors.

The use of ibrutinib (Imbruvica), a BTK inhibitor, is increasing in the first- and second-line. Pinilla-Ibarz says this is where the change of paradigm began for the treatment of CLL. There was also the introduction and approval of other B-cell receptor inhibitors like idealisib. Acalabrutinib (Calquence), which is approved for the treatment of mantle cell lymphoma, is also showing promise in CLL, as well as PI3K delta inhibitors like umbralisib and duvelisib.

Videos

Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the current treatment landscape of chronic lymphocytic leukemia.

Current Treatment Landscape for CLL

Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the biggest challenge in treating patients with chronic lymphocytic leukemia (CLL).

According to Pinilla-Ibarz, the challenges with treating this disease lie in managing, using, and sequencing the various drugs available for these patients. There are a number of mutations found in CLL that can help guide therapy.

Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the biggest challenge in treating patients with chronic lymphocytic leukemia.

Challenges in Treating Patients With CLL

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses how ibrutinib has transformed the treatment landscape of chronic lymphocytic leukemia.

How Ibrutinib Has Transformed the Treatment Paradigm of CLL

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses ongoing research with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.&nbsp;

Javier Pinilla-Ibarz, MD, PhD | Authors

Articles

Current Treatment Landscape for CLL

Challenges in Treating Patients With CLL

How Ibrutinib Has Transformed the Treatment Paradigm of CLL

The Potential of Ibrutinib Combinations for the Treatment of CLL